HERCULES, Calif. / Aug 25, 2025 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that members of the company’s executive leadership team will participate in the following upcoming investor conferences:
2025 Wells Fargo Healthcare Conference
Format: Fireside chat and one-on-one investor meetings
Participants: Norman Schwartz, Chairman and Chief Executive Officer, Roop K. Lakkaraju, Chief Financial Officer
Date and Time: Thursday, September 4, 2025, at 12:45 PM Eastern Time (9:45 AM Pacific Time); a live webcast and subsequent replay of the fireside chat event will be available in the Investor Relations section of Bio-Rad’s website at bio-rad.com
Morgan Stanley 23rd Annual Global Healthcare Conference
Format: One-on-one investor meetings
Participants: Roop K. Lakkaraju, Chief Financial Officer
Date: Tuesday, September 9, 2025
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com
| Last Trade: | US$312.86 |
| Daily Change: | -6.69 -2.09 |
| Daily Volume: | 151,892 |
| Market Cap: | US$6.850B |
October 29, 2025 August 01, 2025 July 28, 2025 July 07, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
